State AIDS Drug Assistance Programs (ADAPs):  A National Status Report on Access – Toplines/Survey

A State-by-State Profile of ADAPs: Key Access & Budget Categories (as of July 1997)

State Financial Eligibility *1
(% above federal poverty level) Medical Eligibility *2
(CD4=CD4 cell count, vl=viral load) Protease Inhibitors Covered *3
(4 drugs approved) Non- nucleosides Covered
(2 drugs approved) OI Prophylaxis Covered *4
(14 drugs recom- mended) Other Medications Covered Total Est. Budget
(FY 1997) State Contri- bution as % of Total Est. Budget
(FY 1997) ADAP Clients Served Per Month *5
(December 1996) Emergency Cost-Containment Measures (1996- 1997) * = measure in place as of July 1997 Alabama 250% CD4 <500 3 0 5 0 $3,190,000 5% 700 Capped enrollment*, waiting list Alaska 200% 4 1 0 0 $122,917 0% 9 Capped enrollment*, transferred funds from other accounts, waiting list Arizona 200% 4 0 2 2 $2,300,027 0% 354 Transferred funds from other accounts Arkansas 100% 0 0 3 3 $1,254,013 0% 389 Capped enrollment California 400% 4 1 13 28 $87,111,105 46% 7,342 Colorado 185% 4 0 0 0 $2,904,932 10% 423 Transferred funds from other accounts Connecticut 300% 3 0 12 42 $3,814,283 0% 548 Delaware 230% 3 1 6 27 $979,000 0% 62 D.C. 300% 3 1 11 25 $4,363,341 3% 699 Access to protease inhibitors capped*; capped enrollment*; reduced formulary*, transferred funds from other accounts, waiting list Florida 200% CD4 <500 4 1 6 2 $24,317,997 0% 4,565 Access to protease inhibitors capped* Georgia 125% CD4 <500 3 0 0 0 $9,379,959 3% 984 Capped enrollment*; restricted access to protease inhibitors*, waiting list Hawaii 400% 4 1 12 13 $1,112,403 27% 66 Idaho 400% CD4 <500 1 0 2 2 $193,000 0% 30 Illinois 200% 4 1 14 36 $14,514,522 57% 1,211 Per client dollar limits on drug costs*; reduced formulary*, transferred funds from other accounts, access to protease inhibitors capped Indiana 300% CD4 <500 4 1 5 4 $2,310,710 3% 225 Capped enrollment*; reduced formulary*, waiting list Iowa 200% 3 0 6 6 $292,680 0% 39 Kansas 300% 4 0 8 14 $738,196 0% 56 Transferred funds from other accounts, capped enrollment, access to protease inhibitors capped Kentucky 300% CD4 <550 4 1 5 7 $994,321 9% 173 Access to protease inhibitors capped*, waiting list Louisiana 200% 3 0 0 0 $19,371,330 83% 115 Transferred funds from other accounts Maine 200% CD4 20k 4 0 5 1 $389,426 15% 45 Access to protease inhibitors capped*, transferred funds from other accounts, waiting list Maryland $8,750 – $29,400 4 1 11 11 $6,259,239 10% 406 Massachusetts <$27,000 p.a. 4 1 10 9 $7,970,714 46% 1,074 Transferred funds from other accounts Michigan 185% <500 CD4 4 1 6 5 $3,258,921 0% 178 Minnesota 300% 4 1 10 22 $841,003 0% 231 Mississippi 200% CD4 30k 1 0 6 2 $2,040,326 0% 415 Access to protease inhibitors capped*, reduced formulary*, transferred funds from other accounts Missouri 185% 4 1 12 47 $2,575,652 23% 842 Access to protease inhibitors capped*, waiting list Montana Need-based 4 0 0 1 $204,000 0% 18 Capped enrollment*, waiting list Nebraska 200% 4 1 6 12 $300,000 0% 59 Reduced formulary Nevada 200% CD4<500 0 0 5 0 $1,534,199 0% 151 Capped enrollment*, waiting list New Hampshire 300% 4 1 10 16 $403,500 0% 40 Restrictions on some formulary drugs*, access to protease inhibitors capped New Jersey <$30,000 p.a. 3 1 11 19 $16,753,868 4% 1,325 Reduced formulary* New Mexico 300% 4 1 9 20 $1,340,212 55% 375 Transferred funds from other accounts New York <$44,000 p.a. 4 2 14 182 $82,501,058 15% 6,183 Transferred funds from other account, reduced formulary North Carolina 125% 4 2 10 7 $3,710,201 20% 310 North Dakota 150% 4 0 13 37 $94,390 0% 14 Ohio 281% 4 1 6 5 $6,600,000 45% 424 Oklahoma 150% 3 0 6 2 $1,690,187 12% 243 Access to protease inhibitors capped*; per client dollar limits on drug costs*, waiting list Oregon 250% 0 0 2 2 $2,035,136 0% 99 Pennsylvania <$30,000 p.a. 3 0 13 30 $9,871,022 47% 1,125 Puerto Rico certified as indigent CD4 10k 3 0 13 87 $15,619,324 46% 2,320 Rhode Island 400% 4 1 9 5 $792,972 0% 57 South Carolina 300% CD4 <500 3 0 6 6 $3,386,578 15% 198 Capped enrollment*, transferred funds from other accounts, waiting list South Dakota 300% 0 1 8 19 $105,343 0% 30 Per client dollar limits on drug costs*; capped enrollment*; reduced formulary* , waiting list Tennessee 300% 3 0 7 4 $1,830,152 0% 147 Restrictions on use of protease inhibitors* Texas 200% 4 1 8 4 $17,088,684 16% 2,727 Reduced formulary*; restrictions on formulary drugs*, transferred funds from other accounts Utah 100% 4 1 0 0 $843,006 14% 79 Transferred funds from other accounts Vermont 200% 4 1 12 14 $374,611 20% 43 Reduced formulary*, waiting list, access to protease inhibitors capped Virginia 200% 4 0 7 1 $6,457,969 11% 700 Reduced formulary*, waiting list, access to protease inhibitors capped Washington 370% 3 1 10 42 $6,863,160 61% 430 transferred funds from other accounts, access to protease inhibitors capped, capped enrollment West Virginia 300% 4 1 2 5 $361,000 7% 39 Transferred funds from other accounts Wisconsin 200% 4 1 6 3 $1,500,001 20% 139 Wyoming 300% 4 0 13 36 $80,940 0% 44 Per client dollar limits on drug costs*, waiting list, capped enrollment

*1 Financial elgibility requirements listed are for a household of one. For more financial eligibility information, including asset limits and sliding scale co-pays, see the full NASTAD/ATDN Technical Report.

*2 All states require a diagnosis of HIV infection for ADAP enrollment.

*3 All state ADAPs cover the five nucleoside analog antiretroviral drugs (AZT, ddI, ddC, d4T, 3TC), except Louisiana where a separate state program provides these drugs through ambulatory care sites.

*4 Based on 1997 USPHS/IDSA Guidelines for the Prevention of Opportunistic Infections for Persons Infected with HIV (released June 27, 1997 MMWR, Vol. 46, No. RR-12).

*5 The number of clients served is usually fifty percent or less of the total enrollment for the month (percentage varies from state to state).
Return to top

State AIDS Drug Assistance Programs: A National Status Report on Access:
Press Release Report State Data